Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1967 8
1968 2
1969 3
1970 3
1971 8
1972 10
1973 10
1974 14
1975 20
1976 19
1977 18
1978 12
1979 9
1980 12
1981 11
1982 11
1983 14
1984 20
1985 13
1986 21
1987 16
1988 21
1989 32
1990 14
1991 30
1992 21
1993 26
1994 22
1995 24
1996 24
1997 39
1998 33
1999 35
2000 23
2001 33
2002 36
2003 48
2004 73
2005 66
2006 84
2007 89
2008 85
2009 70
2010 71
2011 86
2012 81
2013 86
2014 77
2015 58
2016 70
2017 75
2018 58
2019 46
2020 54
2021 46
2022 32
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

1,802 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD.
Barragán E, Breuer D, Döpfner M. Barragán E, et al. J Atten Disord. 2017 Mar;21(5):433-441. doi: 10.1177/1087054713518239. Epub 2016 Jul 28. J Atten Disord. 2017. PMID: 24464327 Clinical Trial.
OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q) with methylphenidate (MPH) and combined MPH + Omega-3/6 in children with ADHD. ...ADHD symptoms were assessed using the ADHD Rating Scale and Clinical Global Impressions-Severity (CGI-S) scale. …
OBJECTIVE: To compare efficacy of Omega-3/6 fatty acids (Equazen eye q) with methylphenidate (MPH) and combined MPH + Omega-3/6 in ch …
Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.
Kis B, Lücke C, Abdel-Hamid M, Heßmann P, Graf E, Berger M, Matthies S, Borel P, Sobanski E, Alm B, Rösler M, Retz W, Jacob C, Colla M, Huss M, Jans T, van Elst LT, Müller HHO, Philipsen A. Kis B, et al. Pharmacopsychiatry. 2020 Nov;53(6):263-271. doi: 10.1055/a-1207-9851. Epub 2020 Oct 5. Pharmacopsychiatry. 2020. PMID: 33017854 Clinical Trial.
INTRODUCTION: The Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS) was a prospective, randomized multicenter clinical trial, comparing methylphenidate (MPH) with placebo (PLAC) in combination with cognitive behavioral group psychotherapy …
INTRODUCTION: The Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS) was a prospective, randomized multicen …
Effects of methylphenidate on reinforcement learning depend on working memory capacity.
Rostami Kandroodi M, Cook JL, Swart JC, Froböse MI, Geurts DEM, Vahabie AH, Nili Ahmadabadi M, Cools R, den Ouden HEM. Rostami Kandroodi M, et al. Psychopharmacology (Berl). 2021 Dec;238(12):3569-3584. doi: 10.1007/s00213-021-05974-w. Epub 2021 Oct 21. Psychopharmacology (Berl). 2021. PMID: 34676440 Free PMC article. Clinical Trial.
The paradigm was designed to disentangle effects on punishment avoidance from effects on reward perseveration. Given the known large individual variability in methylphenidate's effects, we stratified our effects by working memory capacity and trait impulsivity, puta …
The paradigm was designed to disentangle effects on punishment avoidance from effects on reward perseveration. Given the known large individ …
Effectivity of Saffron Extract (Saffr'Activ) on Treatment for Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Clinical Effectivity Study.
Blasco-Fontecilla H, Moyano-Ramírez E, Méndez-González O, Rodrigo-Yanguas M, Martin-Moratinos M, Bella-Fernández M. Blasco-Fontecilla H, et al. Nutrients. 2022 Sep 28;14(19):4046. doi: 10.3390/nu14194046. Nutrients. 2022. PMID: 36235697 Free PMC article. Clinical Trial.
This study compares the efficacy of saffron and the usual treatment with methylphenidate, using objective and pen-and-paper tests. We performed a non-randomized clinical trial with two groups, methylphenidate (n = 27) and saffron (n = 36), in children and adolescent …
This study compares the efficacy of saffron and the usual treatment with methylphenidate, using objective and pen-and-paper tests. We …
Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Ramtvedt BE, Aabech HS, Sundet K. Ramtvedt BE, et al. J Child Adolesc Psychopharmacol. 2014 Apr;24(3):130-9. doi: 10.1089/cap.2013.0114. Epub 2014 Mar 25. J Child Adolesc Psychopharmacol. 2014. PMID: 24666268 Free PMC article. Clinical Trial.
Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events. ...CONCLUSIONS: The availability of both dextroamphetamine and methylphenidate may contribute to minimize adverse events in a subsample of children in pediatric ADHD stim …
Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events. ...CONCLUSIONS: The availability of b …
Mind-Wandering and Childhood ADHD: Experimental Manipulations across Laboratory and Naturalistic Settings.
Merrill BM, Raiker JS, Mattfeld AT, Macphee FL, Ramos MC, Zhao X, Altszuler AR, Schooler JW, Coxe S, Gnagy EM, Greiner AR, Coles EK, Pelham WE Jr. Merrill BM, et al. Res Child Adolesc Psychopathol. 2022 Sep;50(9):1139-1149. doi: 10.1007/s10802-022-00912-6. Epub 2022 Mar 5. Res Child Adolesc Psychopathol. 2022. PMID: 35247108 Clinical Trial.
Methylphenidate significantly reduced RTV among youth with ADHD across self-referential (d = 1.07) and non-self-referential conditions (d = 0.72). In the ADHD classroom study, the significant interaction between mind-wandering condition and methylphenidate indicated
Methylphenidate significantly reduced RTV among youth with ADHD across self-referential (d = 1.07) and non-self-referential condition
Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial.
Konrad K, Günther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B. Konrad K, et al. J Child Adolesc Psychopharmacol. 2005 Apr;15(2):180-90. doi: 10.1089/cap.2005.15.180. J Child Adolesc Psychopharmacol. 2005. PMID: 15910203 Clinical Trial.
The aim of this study was to determine drug-dependent effects on attention and motor activity in children with attention-deficit/hyperactivity disorder (ADHD) in a double-blind methylphenidate (MPH) trial using both subjective behavior ratings and objective measures of fun …
The aim of this study was to determine drug-dependent effects on attention and motor activity in children with attention-deficit/hyperactivi …
Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
Sugaya LS, Salum GA, de Sousa Gurgel W, de Morais EM, Del Prette G, Pilatti CD, Dalmaso BB, Leibenluft E, Rohde LA, Polanczyk GV. Sugaya LS, et al. Lancet Child Adolesc Health. 2022 Dec;6(12):845-856. doi: 10.1016/S2352-4642(22)00279-6. Epub 2022 Oct 26. Lancet Child Adolesc Health. 2022. PMID: 36306807 Clinical Trial.
The primary outcomes were parents' and teachers' composite scores of the Swanson, Nolan, and Pelham-IV scale (SNAP-IV-P/T), the Clinical Global Impressions Severity (CGI-S) scale, and the Children's Global Assessment Scale (CGAS). This trial is registered with Clini …
The primary outcomes were parents' and teachers' composite scores of the Swanson, Nolan, and Pelham-IV scale (SNAP-IV-P/T), the Clinical Glo …
Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/hyperactivity disorder.
Rosenau PT, van den Hoofdakker BJ, Matthijssen AM, van de Loo-Neus GHH, Buitelaar JK, Hoekstra PJ, Dietrich A. Rosenau PT, et al. J Psychiatr Res. 2022 Aug;152:31-37. doi: 10.1016/j.jpsychires.2022.06.014. Epub 2022 Jun 9. J Psychiatr Res. 2022. PMID: 35714551 Free article. Clinical Trial.
Iron and zinc have been associated with attention-deficit/hyperactivity disorder (ADHD), executive functioning, and response to methylphenidate, given their link with the dopaminergic system. This study aimed to investigate the effect of withdrawing methylphenidate
Iron and zinc have been associated with attention-deficit/hyperactivity disorder (ADHD), executive functioning, and response to methylphe
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A, Richard C, Prinzo R, Binder C. Fallu A, et al. Curr Med Res Opin. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906X154132. Curr Med Res Opin. 2006. PMID: 17166338 Clinical Trial.
OBJECTIVE: This pilot, uncontrolled, open-label study evaluated the safety/tolerability and potential effectiveness of OROS-methylphenidate (OROS-MPH) in adult attention deficit hyperactivity disorder (ADHD). ...Statistically significant improvements were observed in execu …
OBJECTIVE: This pilot, uncontrolled, open-label study evaluated the safety/tolerability and potential effectiveness of OROS-methylphenida
1,802 results